5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Dyspnea O
was O
reported O
more O
frequently O
with O
BRILINTA O
than O
with O
control O
agents O
in O
clinical O
trials O
. O

Dyspnea O
resulting O
from O
BRILINTA O
is O
self-limiting O
. O

( O
5.3 O
) O
* O
Severe O
Hepatic O
Impairment O
: O
Likely O
increase O
in O
exposure O
to O
ticagrelor O
. O

( O
5.5 O
) O
5.1 O
General O
Risk O
of O
Bleeding O
Drugs O
that O
inhibit O
platelet O
function O
including O
BRILINTA O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

If O
possible O
, O
manage O
bleeding B-NonOSE_AE
without O
discontinuing O
BRILINTA O
. O

Stopping O
BRILINTA O
increases O
the O
risk O
of O
subsequent O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Concomitant O
Aspirin O
Maintenance O
Dose O
In O
PLATO O
the O
use O
of O
BRILINTA O
with O
maintenance O
doses O
of O
aspirin O
above O
100 O
mg O
decreased O
the O
effectiveness O
of O
BRILINTA O
. O

Therefore O
, O
after O
the O
initial O
loading O
dose O
of O
aspirin O
, O
use O
BRILINTA O
with O
a O
maintenance O
dose O
of O
aspirin O
of O
75-100 O
mg O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
and O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.3 O
Dyspnea O
In O
clinical O
trials O
, O
about O
14 O
% O
of O
patients O
treated O
with O
BRILINTA O
developed O
dyspnea B-OSE_Labeled_AE
. O

Dyspnea B-OSE_Labeled_AE
was O
usually O
mild O
to O
moderate O
in O
intensity O
and O
often O
resolved O
during O
continued O
treatment O
, O
but O
led O
to O
study O
drug O
discontinuation O
in O
0.9 O
% O
of O
BRILINTA O
and O
0.1 O
% O
of O
clopidogrel O
patients O
in O
PLATO O
and O
4.3 O
% O
of O
BRILINTA O
60 O
mg O
and O
0.7 O
% O
on O
aspirin O
alone O
patients O
in O
PEGASUS O
. O

In O
a O
substudy O
of O
PLATO O
, O
199 O
subjects O
underwent O
pulmonary O
function O
testing O
irrespective O
of O
whether O
they O
reported O
dyspnea B-NonOSE_AE
. O

There O
was O
no O
indication O
of O
an O
adverse B-NonOSE_AE
effect I-NonOSE_AE
on I-NonOSE_AE
pulmonary I-NonOSE_AE
function O
assessed O
after O
one O
month O
or O
after O
at O
least O
6 O
months O
of O
chronic O
treatment O
. O

If O
a O
patient O
develops O
new O
, O
prolonged O
, O
or O
worsened O
dyspnea B-NonOSE_AE
that O
is O
determined O
to O
be O
related O
to O
BRILINTA O
, O
no O
specific O
treatment O
is O
required O
; O
continue O
BRILINTA O
without O
interruption O
if O
possible O
. O

In O
the O
case O
of O
intolerable O
dyspnea B-NonOSE_AE
requiring O
discontinuation O
of O
BRILINTA O
, O
consider O
prescribing O
another O
antiplatelet O
agent O
. O

5.4 O
Discontinuation O
of O
BRILINTA O
Discontinuation O
of O
BRILINTA O
will O
increase O
the O
risk O
of O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
stroke B-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

If O
BRILINTA O
must O
be O
temporarily O
discontinued O
( O
e.g. O
, O
to O
treat O
bleeding B-NonOSE_AE
or O
for O
significant O
surgery O
) O
, O
restart O
it O
as O
soon O
as O
possible O
. O

When O
possible O
, O
interrupt O
therapy O
with O
BRILINTA O
for O
five O
days O
prior O
to O
surgery O
that O
has O
a O
major O
risk O
of O
bleeding B-NonOSE_AE
. O

Resume O
BRILINTA O
as O
soon O
as O
hemostasis O
is O
achieved O
. O

5.5 O
Severe O
Hepatic O
Impairment O
Avoid O
use O
of O
BRILINTA O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
is O
likely O
to O
increase O
serum O
concentration O
of O
ticagrelor O
. O

There O
are O
no O
studies O
of O
BRILINTA O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

